Denali Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

DNLI$19.85-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2023	138,385,498	$1,711	$2,144,811	$643	$(1,116,211)	$1,030,954
Issuance of common stock and pre-funded warrants, net of issuance costs of $480	3,244,689	32	499,221	—	—	499,253
Issuances under equity incentive plans	130,214	1	1,021	—	—	1,022
Vesting of restricted stock units	752,455	7	(7)	—	—	—
Stock-based compensation	—	—	27,987	—	—	27,987
Net loss	—	—	—	—	(101,802)	(101,802)
Other comprehensive loss	—	—	—	(1,939)	—	(1,939)
Balance at March 31, 2024	142,512,856	$1,751	$2,673,033	$(1,296)	$(1,218,013)	$1,455,475
Balance at December 31, 2024	144,220,986	$1,768	$2,764,880	$2,020	$(1,538,984)	$1,229,684
Issuances under equity incentive plans	113,792	1	594	—	—	595
Vesting of restricted stock units	916,480	9	(9)	—	—	—
Stock-based compensation	—	—	25,360	—	—	25,360
Net loss	—	—	—	—	(132,970)	(132,970)
Other comprehensive income	—	—	—	17	—	17
Balance at March 31, 2025	145,251,258	$1,778	$2,790,825	$2,037	$(1,671,954)	$1,122,686

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.